Table 3.
Study (year) | Brain tumors (%) | Source† | Techniques | Ref. |
---|---|---|---|---|
Weiss et al. (1976) | 38 ME | Germany | IHC | [104] |
Wang et al. (1998) | 50 CP; 90 EM | USA | PCR and DNA seq | [106] |
Huang et al. (1999) | 25 OL; 32 GA 59 LA, AA, SG; | France | PCR, Southern blotting | [107] |
Vilchez et al. (2003) | 21 | Different‡ | PCR, IHC | [105] |
Rollison et al. (2005) | 1.8 GL, MD | USA | PCR, Southern blotting, qRT-PCR | [108] |
Kim et al. (2002) | 0 | USA | PCR | [109] |
Montesions-Rongen et al. (2004) | 0 | German | PCR | [110] |
Sabatier et al. (2005) | 0 CNS | France | IHC | [111] |
Source: country of origin of the specimens tested in the study.
Assessment of 13 different reports on primary brain tumors from different sources.
AA: Anaplastic astrocytoma; CNS: CNS-related tumor; CP: Choroid plexus tumor; DNA seq: DNA sequence analysis; EM: Ependymoma; GA: Gemistocytic astrocytoma; GL: Glioma; IHC: Immunohistochemistry; LA: Low-grade astrocytoma; MD: Medulloblastoma; ME: Meningioma; OL: Oligodendroglioma; qRT-PCR: Quantitative real-time PCR; SG: Secondary glioblastoma.